Raleigh Capital Management Inc. Pacira Bio Sciences, Inc. Transaction History
Raleigh Capital Management Inc.
- $253 Million
- Q4 2024
A detailed history of Raleigh Capital Management Inc. transactions in Pacira Bio Sciences, Inc. stock. As of the latest transaction made, Raleigh Capital Management Inc. holds 537 shares of PCRX stock, worth $12,404. This represents 0.0% of its overall portfolio holdings.
Number of Shares
537
Previous 537
-0.0%
Holding current value
$12,404
Previous $8,000
25.0%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding PCRX
# of Institutions
260Shares Held
49.8MCall Options Held
1.03MPut Options Held
139K-
Black Rock Inc. New York, NY8.01MShares$185 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.26MShares$122 Million0.0% of portfolio
-
Pacer Advisors, Inc. Malvern, PA3.26MShares$75.4 Million0.15% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY2.26MShares$52.1 Million0.03% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny1.99MShares$46 Million0.06% of portfolio
About Pacira BioSciences, Inc.
- Ticker PCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 45,824,200
- Market Cap $1.06B
- Description
- Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...